IceCure Announces Positive Data from the Largest Multi-Institutional Study of its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials"

Investigator initiated independent study included higher risk patients such as those with metastatic disease, large tumors, and comorbidities, as compared to IceCure's ICE3 study which treated early-stage breast cancer patients Recurrence-free rates were 94.7%, 87.8%, and 81.

8%, at 1, 2, and 3 years, respectively Study published in American Journal of Roentgenology was conducted at 7 U.S. institutions and led by Principal Investigators Dr.

Karim Oueidat and Dr. Robert Ward , both of the Warren Alpert Medical School of Brown University CAESAREA, Israel , Aug. 7, 2024 /PRNewswire/ -- IceCure Medical Ltd.

(Nasdaq: ICCM ) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the publication of an independent study titled "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials: A Multi-institutional Study" in a leading radiology journal, the American Journal of Roentgenology ( AJR ). This multi-institutional study is the largest study of breast cancer cryoablation in women ineligible for prospective clinical trials due to particular patient or tumor characteristics. IceCure's ICE3 study, which evaluated the Company's ProSense® cryoablation system, enrolled early-stage breast cancer patients only.

Based on the ICE3 results, IceCure has filed for regulatory approval of ProSense® in the U.S. for the indication of .